A retrospective, multicenter study of response rates and toxicity profile of RRMM patients treated with daratumumab monotherapy
Latest Information Update: 03 Aug 2021
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 03 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association